Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
A 16 year old male developed symptomatic hypercalcaemia of immobilization on day 47 following a diving accident which had resulted in incomplete C4 tetraplegia. Following initial reduction in serum calcium with salmon calcitonin 100 U/day, symptomatic hypercalcaemia recurred. A single dose of 30 mg pamidronate sodium, given intravenously, caused serum calcium to fall within 48 hours. Initial mild, asymptomatic hypocalcaemia was followed by a return to sustained normocalcaemia. No major adverse reaction was encountered, and if further clinical experience confirms its efficacy, pamidronate sodium will warrant consideration as first-line therapy for immobilization hypercalcaemia.
McIntyre
H D
HD
Department of Endocrinology, Princess Alexandra Hospital, Brisbane, Australia.
Cameron
D P
DP
Urquhart
S M
SM
Davies
W E
WE
D000293:Adolescent; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007103:Immobilization; D007262:Infusions, Intravenous; D008297:Male; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate